ArticleExperimental dermatology2025
A Novel Ammonium Carboxylate Salt of Undecylenic Acid for the Topical Treatment of Gram-Positive and Antibiotic-Resistant Skin Infections.
Article in Experimental dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Condensation of fluconazole and zinc undecylanate particles using low-pressure RF plasma: a novel drug combination approach.BMC pharmacology & toxicology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Uncomplicated topical skin infections like impetigo, caused by gram-positive bacteria such as Staphylococcus aureus and Streptococcus pyogenes, are a common global health issue, particularly affecting children. With increasing antimicrobial resistance, conventional treatments such as mupirocin are becoming ineffective, highlighting the necessity for new antimicrobial development. Fatty acids have long shown potential as novel antimicrobials, but their development has been limited by solubility and efficacy concerns in topical applications. We previously discovered that combining the amino acid L-arginine with an 11-carbon fatty acid, undecylenic acid, produced a water-soluble ammonium carboxylate salt, arginine undecylenate, referred to as GS-1, that elicits potent antimicrobial activity. Under CLSI test conditions, GS-1 showed effective antibacterial activity against clinical isolates of methicillin-sensitive S. aureus (MSSA), methicillin-resistant S. aureus (MRSA), vancomycin-intermediate S. aureus, and S. pyogenes, with MICs of 0.60-1.26 mg/mL and MBCs of 0.63-5.04 mg/mL, respectively. Fluorescence microscopy revealed GS-1 to elicit antibacterial activity by rapidly permeabilising bacterial membranes and inducing reactive oxygen species formation. Serial exposure of 5 MRSA clinical isolates to sub-lethal doses of GS-1 did not appear to induce resistance. In fact, compared to mupirocin, repeated exposures to GS-1 appeared to sensitise bacteria to GS-1. In an animal model of skin infection, topical GS-1 successfully eradicated MRSA from infected, abraded skin after 6 days of treatment with no signs of toxicity. Finally, repeated topical GS-1 exposure in humans caused no irritation or sensitisation. These results support GS-1 as a potential novel topical antibacterial for the treatment of impetigo and other skin infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.